Trial Profile
A Study Investigating Lenvatinib in Combination with Everolimus in Metastatic Renal Cell Carcinoma (mRCC) Resistant to Antiangiogenic Targeted Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Mar 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
- 27 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.